Security record · archived quarter
NRIX
Nurix Therapeutics, Inc. · Healthcare · Biotechnology
14Tracked holders
—Δ holders
12.64MShares held
$263.85MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 80 | +2 | 57.55M | $1.40B | +9 | −7 |
| Q1 2026 | 81 | +9 | 58.06M | $899.96M | +14 | −5 |
| Q4 2025 | 72 | -4 | 55.79M | $1.06B | — | −4 |
| Q3 2025 | 18 | +1 | 36.35M | $335.90M | +1 | — |
| Q2 2025 | 14 | -2 | 38.82M | $442.11M | — | −2 |
| Q1 2025 | 13 | 0 | 15.31M | $181.88M | +1 | −1 |
| Q4 2024 | 13 | -1 | 15.53M | $292.61M | +1 | −2 |
| Q3 2024 | 13 | -1 | 13.04M | $292.98M | +1 | −2 |
| Q2 2024 | 14 | — | 12.64M | $263.85M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 3.20M | — | $66.82M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 3.20M | — | $66.82M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 3.20M | — | $66.82M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 3.20M | — | $66.82M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 3.20M | — | $66.82M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 3.20M | — | $66.82M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 2.84M | — | $59.17M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 2.84M | — | $59.17M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | ARK Investment Management ✦ | 2.32M | — | $48.49M | 0.4% | n/c | 1 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passive) | 1.32M | — | $27.59M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passive) | 1.32M | — | $27.59M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 1.04M | — | $21.72M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 1.04M | — | $21.72M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Millennium Management ✦ | 599.62K | — | $12.51M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Norges Bank ✦ (passive) | 507.54K | — | $10.59M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Renaissance Technologies ✦ | 324.00K | — | $6.76M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | PRIMECAP Management ✦ | 290.00K | — | $6.05M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 60.89K | — | $1.27M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Arrowstreet Capital ✦ | 60.08K | — | $1.25M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Duquesne Family Office ✦ | 44.20K | — | $922,000 | 0.0% | n/c | 1 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 21.30K | — | $444,447 | 0.0% | n/c | 1 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 21.30K | — | $444,447 | 0.0% | n/c | 1 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 21.30K | — | $444,447 | 0.0% | n/c | 1 | SEC ↗ |
| 24 | Gotham Asset Management ✦ | 11.87K | — | $247,769 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 194 holders, 116.98M shares, $1.75B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API